M. Walker (Vancouver, Canada)
The nasal decongestant oxymetazoline prevents inflammatory and oxidative stress responses
I. Beck-Speier, E. Karg, K. L. Maier, M. Behnke, S. M. Koelsch (Neuherberg/Munich, Darmstandt, Germany)
|  |
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma
G. G. Lombardo, L. L. Giannetto, G. R. G. R. Lombardo, O. O. Bertuccio, M. M. Quartarone, P. P. Quattrocchi (Messina, Italy)
| |
Efficiency of once-daily mometasone furoate in school children with seasonal allergic rhinitis and severe nasal congestion
A. Kamenov, S. Cekic (Nis, Serbia And Montenegro)
| |
CS-003, a novel triple neurokinin receptor antagonist, inhibits symptoms of respiratory diseases models in guinea pigs
H. Tsuchida, S. Takahashi, T. Kuraya, K. Morimoto, M. Yamashita (Tokyo, Japan)
| |
Negligible exposure of infants to budesonide via breast milk
A. Falt, T. Bengtsson, A. Gyllenberg, B. Lindberg, K. Strandgarden (Lund, Malmo, Sweden)
| |
Different pharmacological effects of carum copticum on respiratory system
M. H. Boskabady, H. Rakhshandah, P. Jandaghi, S. Kiani, J. Shaikhi, V. Moatamed Shariati, L. Hassanzadah (Mashhad, Islamic Republic Of Iran)
| |
Absence of respiratory effects in asthmatic subjects with the If inhibitor ivabradine, a novel anti-anginal agent
S. K. Babu, S. T. Holgate, F. Gadzik (Southampton, United Kingdom; Bratislava, Slovakia)
| |
Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma
I. Kottakis, A. Nandeuil, H. Raptis, A. Savu, S. E. Linberg, A. A. Woodcock (Parma, Italy; Courbevoie, France; Bucharest, Romania; Rockville, United States Of America; Manchester, United Kingdom)
| |
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma
A. Nandeuil, I. Kottakis, H. Raptis, H. Roslan, Y. Ivanov, A. Woodcock (Courbevoie, France; Parma, Italy; Kuala Lumpur, Malaysia; Pleven, Bulgaria; Manchester, United Kingdom)
| |
Adrenal crisis and hypercorticism induced by inhaled corticosteroids
M. Molimard, C. Pollet, A. Abouelfath, A. Fourrier, F. Haramburu, N. Moore, M. Fayon, A. Tabarin (Bordeaux, France)
| |
Cardiac safety of the novel very long-acting beta2-agonist carmoterol following single rising doses in healthy volunteers
S. E. Linberg, E. R. Heyman, M. A. Nandeuil, I. Kottakis, P. Maison-Blanche (Parma, Italy; Montgomery Village, United States Of America; Paris, France)
| |
Subcutaneous anti-immunoglobulin E (Omalizumab) as a steroid-sparing agent in allergic asthma – a systematic review of randomised controlled trials
S. M. Walker, T. J. Lasserson, M. A. Monteil, K. J. Phelan, E. H. Walters (Warwick, London, United Kingdom; Trinidad, Trinidad And Tobago; Cincinnatti, United States Of America; Hobart, Australia)
| |
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
L. P. Boulet, I. Abdullah, U. Gehling, J. Schlezák, J. M. Echave-Sustaeta, C. Tiesler, R. Engelstätter (Québec City, Canada; Cape Town, South Africa; Schwetzingen, Konstanz, Germany; Komárom, Hungary; Madrid, Spain)
| |
Unbound pharmacologically active metabolite des-CIC is not detectable in human skeletal muscle and subcutaneous adipose tissue after inhalation of high-dose ciclesonide
H. Boss, I. Steiner, R. Nave, A. Drollmann, W. Wurst, C. Joukhadar (Konstanz, Germany; Vienna, Austria)
| |
Comparison of the efficacy and safety of 5 different doses of the novel very long acting β2-agonist carmoterol
I. Kottakis, A. Nandeuil, H. Raptis, S. E. Linberg, J. Bousquet (Parma, Italy; Courbevoie, Montpellier, France; Rockville, United States Of America)
| |
A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma
K. F. Rabe, T. Atienza, P. Magyar, P. Larsson, C. Jorup, U. G. Lalloo (Leiden, Netherlands; Quezon City, Philippines; Budapest, Hungary; Lund, Sweden; Durban, South Africa)
| |
Long-term effect of additional tiotropium bromide on pulmonary function in patients with severe chronic asthma
N. Suzuki, A. Tamura, M. Sasaki, M. Kuramochi, S. Hoshi, C. Ogawa, Y. Sano (Tokyo, Japan)
| |
Effect of inhaled mannitol on the sputum properties in asthmatics with excessive secretions
E. Daviskas, S. D. Anderson, I. H. Young (Sydney, Australia)
| |
Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers
G. Poli, D. Acerbi, F. Nollevaux (Parma, Italy; Wavre, Belgium)
| |
Follow-up results 10 years after early intervention with budesonide or terbutaline in mild persistent asthma
T. Haahtela, K. Tamminen, L. P. Malmberg, P. Rytilä, T. Kava, K. Nikander, T. Persson, O. Selroos (Helsinki, Joensuu, Finland; Lund, Sweden)
| |